Mandelker, Diana http://orcid.org/0000-0003-4154-0567
Marra, Antonio http://orcid.org/0000-0002-7310-7824
Mehta, Nikita
Selenica, Pier
Yelskaya, Zarina
Yang, Ciyu
Somar, Joshua
Mehine, Miika
Misyura, Maksym
Basturk, Olca
Latham, Alicia
Carlo, Maria
Walsh, Michael
Stadler, Zsofia K.
Offit, Kenneth
Bandlamudi, Chaitanya
Hameed, Meera
Chi, Ping
Reis-Filho, Jorge S. http://orcid.org/0000-0003-2969-3173
Ceyhan-Birsoy, Ozge http://orcid.org/0000-0002-9214-1454
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748, P50 CA247749 01)
Marie-Josée and Henry R. Kravis Center for Molecular Oncology, the Precision, Interception and Prevention Program; the Robert and Kate Niehaus Center for Inherited Cancer Genomics
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Breast Cancer Research Foundation
Susan G. Komen
Article History
Received: 21 September 2022
Accepted: 14 December 2022
First Online: 2 January 2023
Competing interests
: J.S.R.-F. reports receiving personal/consultancy fees from Goldman Sachs, REPARE Therapeutics, Paige.AI, Personalis and Eli Lilly, membership of the scientific advisory boards of VolitionRx, REPARE Therapeutics, Paige.AI and Personalis, membership of the Board of Directors of Grupo Oncoclinicas, and ad hoc membership of the scientific advisory boards of Roche Tissue Diagnostics, Ventana Medical Systems, Novartis, Genentech, MSD, Daiichi Sankyo and InVicro, outside the scope of this study. The remaining authors declare no competing interests.